Senti Biosciences Receives Nasdaq Non-Compliance Notices; Secures $2M Note Financing

Senti Biosciences disclosed it received two separate non-compliance notices from Nasdaq for failing to meet the minimum bid price and minimum stockholders' equity requirements. Concurrently, the company amended a securities purchase agreement to authorize the sale of an additional $2.0 million in Senior Secured Convertible Notes.

Key Details

• Nasdaq Notices: On August 27, 2026, Senti received a notice for its stock closing below the $1.00 minimum bid price for 30 consecutive days and a second notice for failing to maintain the minimum $2.5 million stockholders' equity requirement, with a reported deficit of $3.4 million as of June 30, 2026.
• Compliance Deadlines: The company has until February 23, 2027, to regain compliance with the minimum bid price rule and must submit a plan to address the stockholders' equity deficiency by October 11, 2026.
• Financing Agreement: On September 1, 2026, the company amended its Securities Purchase Agreement to permit the sale of $2.0 million in Senior Secured Convertible Notes to a new investor, NSG BioInnovation Fund, L.P. The stock's listing is not immediately affected.